Status: Available
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under an expanded access protocol. Ansuvimab is administered at 50 mg/kg as a single intravenous (IV) infusion
Trial details
Biological sex: AllType: Expanded AccessSponsor: Ridgeback Biotherapeutics, LPUpdated: Dec 17, 2024
Eligibility criteria
Male or female with laboratory confirmed (based on local standard of care) EBOV... [+2]